1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Biocartis Group NV
  6. News
  7. Summary
    BCART   BE0974281132

BIOCARTIS GROUP NV

(BCART)
  Report
Real-time Euronext Bruxelles  -  11:35 2022-08-18 am EDT
1.696 EUR   -0.82%
06/22ADRs End Lower; ArcelorMittal, AstraZeneca Trade Actively
DJ
06/22Biocartis, AstraZeneca To Jointly Develop Companion Lung Cancer Diagnostic Test For Tagrisso
MT
06/22PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso®
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biocartis, AstraZeneca To Jointly Develop Companion Lung Cancer Diagnostic Test For Tagrisso

06/22/2022 | 01:26am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.11% 11014 Delayed Quote.26.78%
BIOCARTIS GROUP NV -0.82% 1.696 Real-time Quote.-52.70%
All news about BIOCARTIS GROUP NV
06/22ADRs End Lower; ArcelorMittal, AstraZeneca Trade Actively
DJ
06/22Biocartis, AstraZeneca To Jointly Develop Companion Lung Cancer Diagnostic Test For Tag..
MT
06/22PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces New Agreement with AstraZeneca for ..
GL
06/22PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces New Agreement with AstraZeneca for ..
AQ
06/22Biocartis Group NV Announces New Agreement with Astrazeneca for the Development and Mar..
CI
06/20Molecular Diagnostics Group Biocartis Introduces Lung Cancer Testing Panel
MT
06/20PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces Launch of its Rapid CE-marked IVD I..
GL
06/20Biocartis Group NV Announces Launch of its Rapid CE-marked IVD Idylla GeneFusion Panel ..
CI
06/20PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces Launch of its Rapid CE-marked IVD I..
GL
06/15PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Reaches Key Commercial Milestones: One-Millio..
GL
More news
Financials
Sales 2022 63,8 M 64,8 M 64,8 M
Net income 2022 -53,0 M -53,9 M -53,9 M
Net Debt 2022 151 M 154 M 154 M
P/E ratio 2022 -1,82x
Yield 2022 -
Capitalization 98,4 M 100 M 100 M
EV / Sales 2022 3,91x
EV / Sales 2023 3,13x
Nbr of Employees 619
Free-Float 86,6%
Chart BIOCARTIS GROUP NV
Duration : Period :
Biocartis Group NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCARTIS GROUP NV
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 1,71 €
Average target price 4,75 €
Spread / Average Target 178%
EPS Revisions
Managers and Directors
Herman Verrelst Chief Executive Officer
Jean-Marc Roelandt Chief Financial Officer
Christian Reinaudo Independent Chairman
Benoit Devogelaere Chief Technology Officer
Piet Houwen Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIOCARTIS GROUP NV-52.70%100
SHOCKWAVE MEDICAL, INC.58.95%10 416
MASIMO CORPORATION-43.46%8 898
NOVOCURE LIMITED9.55%8 699
PENUMBRA, INC.-41.46%6 430
GETINGE AB-43.10%5 918